You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
The Motley Fool's health-care show, Market Checkup, for September 23.
In today's edition of the Motley Fool's health-care show, Market Checkup, analysts Max Macaluso and David Williamson cover an FDA rejection for Merck, approvals for Johnson & Johnson, and a new partnership for AbbVie.
Two game-changing biotech stocks
Alison Southwick has no position in any stocks mentioned. David Williamson owns shares of Pfizer. Max Macaluso, Ph.D. owns shares of Celgene. The Motley Fool recommends Celgene. It recommends and owns shares of Johnson & Johnson. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
